Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA.
Sep 20, 2016
Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH
Sep 12, 2016
Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin
Sep 21, 2016 at 2:30 PM PT
Sep 13, 2016 at 2:55 PM ET